eby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 018781-007210US

Client Ref. No.: T00-023-1

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

JANUARY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Schwendner et al.

Application No.: 10/052,905

Filed: November 2, 2001

For: COMBINATION THERAPY

USING

PENTAFLUOROBENZENESULFONA

MIDES AND ANTINEOPLASTIC

AGENTS

Customer No.: 20350

Confirmation No. 9747

Examiner: Krass, Frederick F.

Technology Center/Art Unit: 1614

<u>AMENDMENT</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed September 17, 2003, please enter the following amendments and remarks. Applicants also submitted another Supplemental Information Disclosure Statement on December 15, 2003.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 10 of this paper.

01/28/2004 YPOLITE1 00000015 201430 10052905

02 FC:1202

18.00 DA